CSS
SRPT icon

Cubist Systematic Strategies’s Sarepta Therapeutics SRPT Stock Holding History

Cubist Systematic Strategies’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$212K Sell
11,000
-4,000
-27% -$71.3K ﹤0.01% 2636
2025
Q2 		$257K Buy
+15,000
New +$640K ﹤0.01% 2508
2023
Q3 		– Sell
-1,600
Closed -$183K – 3869
2023
Q2 		$183K Buy
+1,600
New +$206K ﹤0.01% 2848

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cubist Systematic Strategies's SRPT Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 49,803 shares — an estimated $888K sold.

Cubist Systematic Strategies first reported a position in SRPT in Q2 2014 and held it in 39 quarters. The position peaked at $23.4M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 49,803 Sarepta Therapeutics shares in Q3 2025, an estimated $888K.
  • Cubist Systematic Strategies first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 39 quarters.
  • Cubist Systematic Strategies's Sarepta Therapeutics position peaked at $23.4M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.